Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has introduced a generic version of Concerta (methylphenidate hydrochloride extended-release tablets), under its pact with Ortho-McNeil-Janssen Pharmaceuticals (OMJPI).
Subscribe to our email newsletter
Concerta is a prescription product indicated as the treatment for attention deficit hyperactivity disorder (ADHD) for children ages 6 to 17 and in adults 18 to 65 as part of a total treatment program that may include counseling or other therapies.
As per the terms of the agreement, Watson markets and distributes the product in the US, however the product will be manufactured and supplied by OMJPI to Watson with all dosage strengths of the authorized generic product.
OMJPI will receive a share of the net sales from Watson’s sales of the product.
Watson has the option to continue to pursue US Food and Drug Administration approval of its abbreviated new drug application (ANDA) for a generic version of Concerta and may launch its own ANDA product at the conclusion of the exclusive supply agreement.